ATA136098A - Formulierungen mit probiotisch wirksamen mikroorganismen - Google Patents

Formulierungen mit probiotisch wirksamen mikroorganismen

Info

Publication number
ATA136098A
ATA136098A AT0136098A AT136098A ATA136098A AT A136098 A ATA136098 A AT A136098A AT 0136098 A AT0136098 A AT 0136098A AT 136098 A AT136098 A AT 136098A AT A136098 A ATA136098 A AT A136098A
Authority
AT
Austria
Prior art keywords
probiotally
formulations
effective microorganisms
microorganisms
effective
Prior art date
Application number
AT0136098A
Other languages
English (en)
Other versions
AT407008B (de
Original Assignee
Viernstein Helmut Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viernstein Helmut Dr filed Critical Viernstein Helmut Dr
Priority to AT0136098A priority Critical patent/AT407008B/de
Priority to EP99938048A priority patent/EP1102580A2/de
Priority to AU52704/99A priority patent/AU5270499A/en
Priority to PCT/AT1999/000192 priority patent/WO2000007571A2/de
Publication of ATA136098A publication Critical patent/ATA136098A/de
Application granted granted Critical
Publication of AT407008B publication Critical patent/AT407008B/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/065—Microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AT0136098A 1998-08-06 1998-08-06 Formulierungen mit probiotisch wirksamen mikroorganismen AT407008B (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AT0136098A AT407008B (de) 1998-08-06 1998-08-06 Formulierungen mit probiotisch wirksamen mikroorganismen
EP99938048A EP1102580A2 (de) 1998-08-06 1999-07-29 Formulierungen mit probiotisch wirksamen mikroorganismen
AU52704/99A AU5270499A (en) 1998-08-06 1999-07-29 Formulations having probiotically active microorganisms
PCT/AT1999/000192 WO2000007571A2 (de) 1998-08-06 1999-07-29 Formulierungen mit probiotisch wirksamen mikroorganismen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0136098A AT407008B (de) 1998-08-06 1998-08-06 Formulierungen mit probiotisch wirksamen mikroorganismen

Publications (2)

Publication Number Publication Date
ATA136098A true ATA136098A (de) 2000-04-15
AT407008B AT407008B (de) 2000-11-27

Family

ID=3512210

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0136098A AT407008B (de) 1998-08-06 1998-08-06 Formulierungen mit probiotisch wirksamen mikroorganismen

Country Status (4)

Country Link
EP (1) EP1102580A2 (de)
AT (1) AT407008B (de)
AU (1) AU5270499A (de)
WO (1) WO2000007571A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767203B2 (en) * 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
CA2416120A1 (en) * 2000-07-17 2002-01-24 Svend Laulund Methods and formulations with probiotic microorganisms and medicaments
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
EP1287745A1 (de) 2001-08-24 2003-03-05 The Procter & Gamble Company Kaubare Zusammmensetzung mit Probiotika
DE102006054260A1 (de) * 2006-02-28 2007-09-27 Lohmann Animal Health Gmbh & Co. Kg Wasser stabilisierende Zusammensetzung, Verfahren zu deren Herstellung und deren Verwendung
PL2318511T3 (pl) * 2008-08-28 2018-01-31 Chr Hansen As Kompozycja bakteryjna
JP2012518394A (ja) * 2009-02-23 2012-08-16 セーホーエル．ハンセン アクティーゼルスカブ 乳酸菌組成物の製造方法
FR2963239B1 (fr) * 2010-08-02 2013-03-08 Vetalis Formes galeniques effervescentes solides pour animaux
KR102435108B1 (ko) 2010-08-04 2022-08-22 핀치 테라퓨틱스 홀딩스 엘엘씨 분변 세균총 이식을 위한 조성물, 그의 제조 방법과 사용 방법, 및 그를 전달하기 위한 장치
TR201007613A2 (tr) * 2010-09-16 2012-04-24 Yed�Tepe �N�Vers�Tes� Liyofilize biyopestisit efervesan granül ve üretim yöntemi
CN103561752B (zh) 2011-03-09 2016-04-20 明尼苏达大学评议会 用于移植结肠微生物群的组合物和方法
WO2013176774A1 (en) 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
CN103550401B (zh) * 2013-11-19 2016-06-22 浙江美保龙生物技术有限公司 一种复合微生态制剂泡腾片的制备方法
WO2015154140A1 (en) * 2014-04-09 2015-10-15 Kambouris Shares Pty Ltd Methods and compositions for delivering a probiotic
CA2985827A1 (en) 2015-05-14 2016-11-17 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
NZ776366A (en) 2015-05-22 2023-02-24 Univ Minnesota Methods for treating autism spectrum disorder and associated symptoms
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
US11026978B2 (en) 2016-10-11 2021-06-08 Finch Therapeutics Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
CA3058818A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating parkinson's disease (pd) and related disorders
CA3064773A1 (en) 2017-05-26 2018-11-29 Crestovo Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
CA3072032A1 (en) 2017-08-07 2019-02-14 Finch Therapeutics, Inc. Compositions and methods for maintaining and restoring a healthy gut barrier
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
CA3114423A1 (en) 2018-09-27 2020-04-02 Finch Therapeutics Holdings Llc Compositions and methods for treating epilepsy and related disorders
CA3147629A1 (en) 2019-07-19 2021-01-28 Finch Therapeutics Holdings Llc. Methods and products for treatment of gastrointestinal disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1061894A (en) * 1963-03-01 1967-03-15 Lucien Nouvel Therapeutically active bacterial preparations
FR3626M (fr) * 1963-11-13 1965-10-18 Lucien Nouvel Médicament pour affections intestinales.
FI840816A0 (fi) * 1984-03-01 1984-03-01 Farmos Oy Bakteriepreparat
EP0203586A3 (de) * 1985-05-29 1988-03-09 Pioneer Hi-Bred International Zubereitung für die Behandlung von Magen-/Darmstörungen bei Tieren
GB8908361D0 (en) * 1989-04-13 1989-06-01 Beecham Group Plc Composition
DE4033996A1 (de) * 1990-10-25 1992-04-30 Karl Heinz Hoelzel Enzymatisches stoffwechselprodukt zur symbioselenkung und verfahren zu seiner herstellung
US5340577A (en) * 1992-07-29 1994-08-23 The United States Of America, As Represented By The Secretary Of Agriculture Probiotic for control of salmonella
EP0686039B1 (de) * 1993-02-24 2000-08-23 Valio Ltd. Methode zur verstärkung der immunantwort auf orale vakzine
US5785990A (en) * 1995-07-10 1998-07-28 Merrick's, Inc. Feed fortifier and enhancer for preruminant calves and method of using same
AT405235B (de) * 1995-11-02 1999-06-25 Helmut Dr Viernstein Probiotisch wirksame formulierung
FR2770778B1 (fr) * 1997-11-12 2000-05-26 Investigations Therapeutiques Composition pour le traitement des gastro-enterites aigues, procede de fabrication de cette composition et solution de traitement obtenue a partir de cette composition

Also Published As

Publication number Publication date
EP1102580A2 (de) 2001-05-30
WO2000007571A2 (de) 2000-02-17
AU5270499A (en) 2000-02-28
AT407008B (de) 2000-11-27
WO2000007571A3 (de) 2000-05-11

Similar Documents

Publication Publication Date Title
FI981065L (fi) Monipistelähetys
IS5555A (is) Selekoxib lyfjablöndur
ID30031A (id) Formulasi-formulasi agrokimia
ID23546A (id) Formulasi-formulasi ziprasidon
BR9705102A (pt) Implemento de lavrar
NO20004240L (no) Formuleringer
ATE224703T1 (de) Brauseformulierungen
PT1130966E (pt) Formulacoes antiparasitarias
AU5270499A (en) Formulations having probiotically active microorganisms
DE69911858D1 (de) Entschachtelungsvorrichtung
DE69919255D1 (de) Graviervorrichtung
DE69902440D1 (de) Rollstuhl
DE69941126D1 (de) Cytokinerezeptor zalpha11
DE59913708D1 (de) Bakterielle transglutaminasen
DE69931852D1 (de) Xylitol produzierende Mikroorganismen
GB2339576B (en) Biomass treatment
DE59812000D1 (de) Bakterielle plasmide
BR9707770A (pt) Tifluzamida com eficácia aperfeiçoada
GB9800954D0 (en) Well treatment with micro-organisms
DE69931607D1 (de) Lipasevariante
PT1102746E (pt) Fenilamidinas substituidas com accao antitrombotica
NO20012476D0 (no) Rullestol
DE59805361D1 (de) Sterilisierbehälter
NO980270L (no) Trekkanordning
DE69910683D1 (de) Sähmaschine

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee